EA200301195A1 - Применение энантиомерно чистого эсциталопрама - Google Patents
Применение энантиомерно чистого эсциталопрамаInfo
- Publication number
- EA200301195A1 EA200301195A1 EA200301195A EA200301195A EA200301195A1 EA 200301195 A1 EA200301195 A1 EA 200301195A1 EA 200301195 A EA200301195 A EA 200301195A EA 200301195 A EA200301195 A EA 200301195A EA 200301195 A1 EA200301195 A1 EA 200301195A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disorders
- escytal
- enantiomerally
- prema
- clean
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 abstract 3
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010029333 Neurosis Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 abstract 1
- 229960004341 escitalopram Drugs 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 229940127021 low-dose drug Drugs 0.000 abstract 1
- 208000015238 neurotic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100684 | 2001-05-01 | ||
| PCT/DK2002/000281 WO2002087566A1 (en) | 2001-05-01 | 2002-05-01 | The use of enantiomeric pure escitalopram |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200301195A1 true EA200301195A1 (ru) | 2004-04-29 |
Family
ID=8160464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200301195A EA200301195A1 (ru) | 2001-05-01 | 2002-05-01 | Применение энантиомерно чистого эсциталопрама |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US20040198809A1 (enExample) |
| EP (1) | EP1385503A1 (enExample) |
| JP (1) | JP2004527551A (enExample) |
| KR (2) | KR20100012089A (enExample) |
| CN (1) | CN1509169A (enExample) |
| AR (1) | AR033308A1 (enExample) |
| AT (1) | AT10974U1 (enExample) |
| BG (1) | BG108379A (enExample) |
| BR (1) | BR0208283A (enExample) |
| CA (1) | CA2445843A1 (enExample) |
| CZ (1) | CZ20033267A3 (enExample) |
| EA (1) | EA200301195A1 (enExample) |
| HR (1) | HRP20030744A2 (enExample) |
| HU (1) | HUP0400054A3 (enExample) |
| IL (1) | IL158031A0 (enExample) |
| IS (1) | IS6954A (enExample) |
| ME (1) | MEP5908A (enExample) |
| MX (1) | MXPA03008777A (enExample) |
| NO (1) | NO20034538D0 (enExample) |
| PL (1) | PL367480A1 (enExample) |
| SK (1) | SK14612003A3 (enExample) |
| UA (1) | UA82828C2 (enExample) |
| WO (1) | WO2002087566A1 (enExample) |
| YU (1) | YU85303A (enExample) |
| ZA (1) | ZA200307102B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| CN1509169A (zh) * | 2001-05-01 | 2004-06-30 | H��¡�±�������˾ | 对映体纯艾司西酞普兰的用途 |
| MXPA05005772A (es) * | 2002-12-23 | 2005-08-16 | Lundbeck & Co As H | Bromhidrato de escitalopram y un metodo para su preparacion. |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| ES2515092T3 (es) * | 2003-12-11 | 2014-10-29 | Sunovion Pharmaceuticals Inc. | Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión |
| EA200601641A1 (ru) * | 2004-03-05 | 2006-12-29 | Х. Лундбекк А/С | Кристаллическая композиция, содержащая оксалат эсциталопрама |
| US20050196453A1 (en) | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
| TWI358407B (en) * | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| US20070112075A1 (en) * | 2005-10-14 | 2007-05-17 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
| CA2625835A1 (en) | 2005-10-14 | 2007-05-10 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| CN100353939C (zh) * | 2006-01-05 | 2007-12-12 | 昆明积大制药有限公司 | 含西酞普兰和环糊精的抗抑郁口服药用组合物 |
| US20070259952A1 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Uses of escitalopram |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| EP2086509A1 (en) * | 2006-10-20 | 2009-08-12 | Ratiopharm GmbH | Escitalopram and solid pharmaceutical composition comprising the same |
| JP5404048B2 (ja) * | 2006-10-27 | 2014-01-29 | 久光製薬株式会社 | 貼付剤 |
| EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
| MY157192A (en) * | 2007-08-03 | 2016-05-13 | Richter Gedeon Nyrt | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| EP2248808B1 (en) * | 2008-01-31 | 2014-07-16 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| ITMI20080768A1 (it) * | 2008-04-24 | 2009-10-25 | Abiogen Pharma Spa | Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one |
| WO2010098230A1 (ja) * | 2009-02-27 | 2010-09-02 | 久光製薬株式会社 | 経皮投与製剤 |
| US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| EP3294337B1 (en) * | 2015-05-13 | 2024-12-18 | Arvid Carlsson Research AB | Treatment of debilitating fatigue by combined use of 3(s)-3-[3-(methylsulfonyl)phenyl]-1- propylpiperidine and an anti-depressive agent |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1143703A (enExample) * | 1965-03-18 | |||
| US4079135A (en) * | 1973-12-13 | 1978-03-14 | Imperial Chemical Industries Limited | Morpholine derivatives as antidepressants |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
| US5958429A (en) * | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
| US6069177A (en) * | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
| SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| UA62984C2 (en) * | 1997-11-11 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
| JP2002519321A (ja) * | 1998-06-30 | 2002-07-02 | イーライ・リリー・アンド・カンパニー | セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体 |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| SK285719B6 (sk) * | 1998-10-20 | 2007-07-06 | H. Lundbeck A/S | Spôsob prípravy citalopramu a medziprodukty |
| EP1173431B2 (en) * | 1999-04-14 | 2009-08-26 | H. Lundbeck A/S | Method for the preparation of citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| EP1276478A2 (en) * | 2000-04-24 | 2003-01-22 | ARYx Therapeutics | (2-aminoethyl) oxime derivatives for the treatment of depression |
| CN1509169A (zh) * | 2001-05-01 | 2004-06-30 | H��¡�±�������˾ | 对映体纯艾司西酞普兰的用途 |
-
2002
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Ceased
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko not_active Ceased
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en not_active Ceased
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-01 PL PL02367480A patent/PL367480A1/xx not_active Application Discontinuation
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
-
2003
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-10-09 NO NO20034538A patent/NO20034538D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
-
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
-
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0208283A (pt) | 2004-03-09 |
| US20040198810A1 (en) | 2004-10-07 |
| US20040198811A1 (en) | 2004-10-07 |
| MEP5908A (xx) | 2010-02-10 |
| NO20034538L (no) | 2003-10-09 |
| BG108379A (bg) | 2004-11-30 |
| IL158031A0 (en) | 2004-03-28 |
| EP1385503A1 (en) | 2004-02-04 |
| US20040192764A1 (en) | 2004-09-30 |
| CZ20033267A3 (en) | 2004-06-16 |
| JP2004527551A (ja) | 2004-09-09 |
| UA82828C2 (en) | 2008-05-26 |
| KR20040030609A (ko) | 2004-04-09 |
| HUP0400054A3 (en) | 2007-03-28 |
| CN1509169A (zh) | 2004-06-30 |
| US20040192765A1 (en) | 2004-09-30 |
| US20040198809A1 (en) | 2004-10-07 |
| HRP20030744A2 (en) | 2005-06-30 |
| KR20100012089A (ko) | 2010-02-05 |
| MXPA03008777A (es) | 2004-02-12 |
| WO2002087566A1 (en) | 2002-11-07 |
| AT10974U1 (de) | 2010-02-15 |
| YU85303A (sh) | 2006-05-25 |
| CA2445843A1 (en) | 2002-11-07 |
| IS6954A (is) | 2003-09-15 |
| US20080004338A1 (en) | 2008-01-03 |
| US20040192766A1 (en) | 2004-09-30 |
| NO20034538D0 (no) | 2003-10-09 |
| AR033308A1 (es) | 2003-12-10 |
| HUP0400054A2 (hu) | 2004-04-28 |
| PL367480A1 (en) | 2005-02-21 |
| SK14612003A3 (sk) | 2004-04-06 |
| ZA200307102B (en) | 2004-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200301195A1 (ru) | Применение энантиомерно чистого эсциталопрама | |
| ATE554779T1 (de) | Krill zur prävention und/oder behandlung von herz-kreislauf-erkrankungen | |
| EA200601553A1 (ru) | Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды | |
| DE60035232D1 (de) | (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom | |
| DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| ATE325612T1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
| DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| EA200001218A1 (ru) | Комбинационная терапия для лечения резистентной депрессии | |
| UA70925C2 (uk) | Спосіб лікування естрогенстимульованого раку | |
| DE60200492D1 (de) | Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen | |
| EA200500782A1 (ru) | Лечение геморрагического шока | |
| NO20054744L (no) | Behandling av Alzheimers sykdom | |
| EE200400005A (et) | Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine | |
| ATE355054T1 (de) | Verfahren und verbindungen zur behandlung der depression | |
| ATE473728T1 (de) | Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare | |
| ATE411984T1 (de) | Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten | |
| EA200501528A1 (ru) | Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний | |
| EA200501802A1 (ru) | Сочетание аналептина модафинила и антидепрессанта для лечения депресии | |
| NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
| ATE305311T1 (de) | Zusammensetzung zur behandlung von herzinsuffizienz | |
| MXPA03008039A (es) | Polipeptidos de serpina humanos. | |
| EA200601238A1 (ru) | Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела |